ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets
Business/EarningsArticle

CVS Group reports 5.9% revenue rise as shares fall 5.7%

The UK veterinary services firm posted 5.9% higher revenue and 5.1% higher adjusted EBITDA for FY2026, but its stock slipped to £1,228, down 5.67% on the day.

PA
Priya Anand · Equities & Earnings Desk · 26 Sept 2026 · 12:08 · 2 min read
Share
CVS Group reports 5.9% revenue rise as shares fall 5.7%

CVS Group Plc announced FY2026 results on September 24, 2026. Revenue reached GBP 712.8 million, up 5.9% year‑on‑year, while adjusted EBITDA rose 5.1% to GBP 141.5 million. Adjusted earnings per share were 85.6 pence, a 6.9% increase.

The company’s share price fell 5.67% to £1,228.14, a drop of about $73.86 per share, after closing at £1,302 the day before. The stock now sits within a 52‑week range of £1,062 to £1,648, roughly 15.7% above its low and 25.5% below its high.

Like‑for‑like growth was modest, with first‑half growth of about 2.7% and second‑half performance dampened by extreme weather in the United Kingdom during May‑July. August trading recovered to match the first‑half pace.

In FY2026 the group completed six acquisitions in Australia covering 14 sites for GBP 43.3 million, and signed two further deals after the year‑end. In the United Kingdom it agreed to acquire two sites for an initial GBP 15 million, its first UK purchase in several years. Management reaffirmed a GBP 50 million capital‑allocation target for future deals, noting leverage could temporarily exceed its 2‑times balance‑sheet ceiling if transactions are accretive.

RDEC tax‑credit income fell slightly to GBP 15.1 million from GBP 15.7 million in FY2025, with FY2027 expectations around GBP 15 million. The company introduced a new Chief Client Officer role to oversee central marketing and client‑relationship management.

CEO Richard Fairman highlighted the revenue and EBITDA growth, attributing it to all three divisions and noting continued inflationary pressure on margins. He also reiterated interest in further Australian opportunities. Chief Veterinary Officer Paul Higgs commented on improving veterinary‑staff availability and the need to rebuild professional trust following the Competition and Markets Authority (CMA) review, which the company said has now concluded with remedies in place.

InvestingPro rated CVS Group’s financial‑health score as “GOOD” and set price targets between $18.54 and $26.48, implying about 25% upside. The stock’s beta is 1.07.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT